| Literature DB >> 32486469 |
Benjamin Marchandot1, Laurent Sattler2, Laurence Jesel1,3, Kensuke Matsushita1,3, Valerie Schini-Kerth3, Lelia Grunebaum2, Olivier Morel1,3.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.Entities:
Keywords: COVID-19; antiphospholipid antibodies; coronavirus disease 2019; endothelium; hemostasis; microparticles; thrombosis
Year: 2020 PMID: 32486469 DOI: 10.3390/jcm9061651
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241